HGH Injections For Sale

The Acromegaly Market is expected to show positive growth in the forecast period (20222032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

Acromegaly Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. This Acromegaly Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Acromegaly Market report analysis.

Key takeaways from Acromegaly Market Research Report

Know which therapies are expected to grab major Acromegaly Market Share @ Acromegaly Market Research Report

Acromegaly Overview

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.

Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients are not able to put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth.

Surgery is the treatment of choice for all microadenomas as well as macroadenomas, causing a mass effect. Debulking of macroadenomas without mass effect can also be done and has been described as a modality to allow for better response to medical treatment even if a surgical cure is not likely. The best predictors of surgical cure include smaller tumor size, lower levels of GH/IGF-1, and absence of invasion of surrounding structures such as the cavernous sinus. All of these drugs are synthetic somatostatin and bind to somatostatin receptors.

Acromegaly Epidemiology Insights

Acromegaly is a very rare disorder caused, in most cases, by a tumor of the pituitary gland that produces too much growth hormone (GH). Nearly all pituitary tumors, including those that cause acromegaly, are benign, and not malignant. However, they can become quite large and expand beyond the normal confines of the pituitary gland.

Acromegaly Epidemiology Segmentation in the 7MM

For further information of this report to understand which factors are driving Acromegaly Epidemiology trends @ Acromegaly Epidemiological Insights

Acromegaly Treatment Market

The current treatment method for Acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas, and on reducing GH and IGF-1 levels to normal. Although, the primary treatment method for Acromegaly is transsphenoidal surgery, although all the patients are not eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery. The cure rate of surgery is about 80% for microadenomas and 4050% for macroadenomas.

Acromegaly Pipeline Companies

Acromegaly Market Insights

As per the literature reviews by Lim et al., titled The role of combination medical therapy in the treatment of acromegaly, pegvisomant and SSA combination has demonstrated good biochemical control in the majority of patients, and may allow individual drug dosage reductions, but patients require close monitoring for liver enzyme elevations. The combination of cabergoline, to SSA is relatively well tolerated and most likely to be effective in patients with very mild IGF-1 elevations. It was also found that the combination of pegvisomant and cabergoline may be useful in a select group of patients with mild IGF-1 elevations, particularly in the setting of intolerance to SSA or when the cost of SSA-Peg therapy is prohibitive.

Learn more about the Acromegaly Therapies in clinical trials @ Drugs for Acromegaly Treatment

Acromegaly Emerging Therapies

The emerging therapies for the treatment of Acromegaly includes Octreotide capsules (Chiasma Pharma), Veldoreotide (Strongbridge Biopharma), CAM2029 (Camurus), CRN00808 (Crinetics Pharmaceuticals), IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), and MTD201 (Midatech). Octreotide capsules have been granted orphan designation in the US and the European Union for the potential treatment of Acromegaly.

Scope of the Acromegaly Market Research Report

Discover more about Acromegaly Medications in development @ Acromegaly Clinical Trials

Table of Content

1. Key Insights

2. Acromegaly Executive Summary

3. Competitive Intelligence Analysis

4. Acromegaly: Market Overview at a Glance

5. Acromegaly: Disease Background and Overview

6. Patient Journey

7. Acromegaly Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acromegaly Unmet Needs

10. Key Endpoints of Acromegaly Treatment

11. Acromegaly Marketed Products

12. Acromegaly Emerging Therapies

13. Acromegaly: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acromegaly Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Acromegaly Market Drivers

19. Acromegaly Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Get in touch with our Business Executive @ Acromegaly Market Trend

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/

Read this article:

Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) - Digital Journal

No, those steroid-fueled home run hitters don't count

Aaron Judge just made history during the Yankees game against the Toronto Blue Jays. Officially, he tied the all-time American League (and New York Yankees) record for most home runs in a season, held by Roger Maris since 1961. But for baseball purists (like my editor who forced me to write that headline), Judge tied the record for all-time home runs in a season league-wide.

During the 7th inning against the Toronto Blue Jays, the California native hit the ball over the bullpen and against the left field wall, marking his 61st home run this season. The two-run homer broke a three-three tie and cemented Judges place in the history books. Earlier this month, he tied Babe Ruths nearly century-old 60-home run mark, becoming the third Yankee to hit 60 homers.

The official record-holder is San Francisco Giants legend Barry Bonds, who broke the record in 2001, hitting 73 homers in a single season. The catch? Homie was juiced on steroids and other banned substances. According to Forbes, Bonds used injectable anabolic steroids, injectable human growth hormone, post cycle therapy drugs, and amphetamines, between 2001 and 2006, when he reached the No. 1 ranking for all-time home runs at 762.

Judge who has played for the Yankees since 2016 has been selected as an MLB All-Star four times: in 2017, 2018, 2021, and 2022. He was also the American League home run leader and Rookie of the Year in 2017.

Read more here:

Aaron Judge Ties the Real Home Run Record - Rolling Stone

ReportLinker

Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others.

New York, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By Product, By Application, By Regional Outlook and Forecast, 2022 2028" - https://www.reportlinker.com/p06322275/?utm_source=GNW These medications could greatly enhance human health. Protein distribution in appropriate amounts to the body to enable the precise functioning of various glands, as well as other organs in the body, is the basic concept behind protein therapy, which is conceptually related to gene therapy.

Genetically modified versions of naturally produced human proteins are called therapeutic proteins. They can be utilized to swap out proteins that are defective or lacking in a particular condition. They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness. The proteins produced by genetic engineering can be made to closely match the natural proteins they are meant to replace, or they can be improved by the addition of sugars and other compounds that prolong the proteins activity.

A protein that is defective or lacking in a certain condition can be replaced with therapeutic proteins. They can also increase the bodys production of a helpful protein to lessen the effects of illness or chemotherapy. The proteins produced by genetic engineering may closely resemble the natural proteins they are intended to replace, or they may be improved.

Covid-19 Impact Analysis

The COVID-19 pandemic severely hampered the economy all over the world. A number of businesses were significantly demolished by the abrupt emergence of the pandemic. Moreover, several manufacturing and production facilities were closed owing to the outbreak due to the lockdown imposed by various governments within their countries. The protein therapeutics market was also disrupted in the initial period of the pandemic. Lockdown caused major delays within the development and delivery of crucial medical supplies. Attributed to this, the production of therapeutic protein was impeded.

Market Growth Factors

An increase in the cases of cancer across the world

One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world. Any disease that can affect any region of the body is referred to as cancer. Neoplasms and malignant tumors are other words that are used to denote this disease. One characteristic of cancer is the quick development of aberrant cells that expand outside of their normal borders, infiltrate other body components, and eventually move to other organs. This process is known as metastasis. The main reason why cancer patients die is because of widespread metastases within their bodies.

Rising focus of governments and regulatory bodies in accelerating the process of approval for this practice

A significant number of people in various developed, as well as developing nations who suffer from uncommon and complex diseases, depend on plasma-derived therapies every day as essential, life-saving medications. The need for these treatments, in particular immunoglobulins, has grown significantly and is still growing on a global scale. Plasma-derived therapies are treatments made from human plasma through a fractionation procedure in which the pertinent plasma proteins are isolated. The single largest component of human blood is called plasma, which is made up of proteins, salts, enzymes, and water. Primary and secondary immunodeficiencies, bleeding disorders, inhibitor deficiencies, and other rare diseases are all treated with plasma-derived medicines.

Market Restraining Factors

High manufacturing and administration cost

A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies. Because of high product prices, some therapies that patients need for a speedy and complete recovery are no longer available. In several nations, prices are additionally governed by law. Through their authority over national healthcare organizations, which can cover a significant portion of the cost of distributing drugs to consumers, government bodies restrict costs.

Product Outlook

On the basis of Product, the Protein Therapeutics Market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. In 2021, the Insulin segment garnered a significant revenue share of the protein therapeutics market. The rise in the growth of the segment is majorly attributed to the increasing cases of diabetes all over the world. Insulin is a natural hormone, which is produced by the pancreas. The lack of production of this hormone is the factor that stimulates the diabetes level of the human body.

Application Outlook

By application, the Protein Therapeutics Market is segregated into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others. In 2021, the metabolic disorders segment procured the biggest revenue share of the protein therapeutics market. The rise in the growth of the segment is due to the exponential demand for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segments growth.

Regional Outlook

Region-wise, the Protein Therapeutics Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America held the largest revenue share of the protein therapeutics market. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. Moreover, North American countries are early adopters of several new technologies and approaches.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Protein Therapeutics Market. Companies such as Merck & Co., Inc. Amgen, Inc., Eli Lilly and Company are some of the key innovators in Protein Therapeutics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.

Recent Strategies Deployed in Protein Therapeutics Market

Partnership, Collaboration and Agreements:

Aug-2022: Merck came into a collaboration with Orna Therapeutics, a biotechnology company. Following this collaboration, the companies would work on the discovery, development, and commercialization of multiple programs, encompassing therapeutics and vaccines in the sector of infectious disease and oncology.

Mar-2022: Novo Nordisk joined hands with Massachusetts Institutes of Technology and Brigham and Womens Hospital. Through this collaboration, the company aimed to leverage the distinct prospect to bring new transformational solutions to patients by utilizing its distinct capabilities.

Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.

Jan-2022: Merck teamed up with Absci, the drug, and target discovery company. Following this collaboration, Merck aimed to leverage Abscis platform to utilize its compelling opportunity intending to develop new biologic candidates as well as explore complex protein expression.

Aug-2021: Eli Lilly and Company joined hands with Lycia Therapeutics, a biotechnology company. Following this collaboration, the companies aimed to focus on the development, manufacturing, and marketing of new targeted therapeutics leveraging the proprietary lysosomal targeting chimera protein degradation technology of Lycia.

Sep-2020: Merck collaborated with Seattle Genetics, an American biotechnology company. With this collaboration, the companies aimed to further expand the oncology portfolio of Merck in order to enhance the lives of cancer patients.

Acquisition and Mergers:

Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to integrate RSV investigational treatments of ReViral into its portfolio in order to acquire an offering of promising therapeutic candidates.

Nov-2021: Pfizer took over Trillium Therapeutics, a clinical-stage immuno-oncology company. This acquisition aimed to offer an impressive portfolio, including biologics, to Pfizer

Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobios antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.

Jul-2021: Eli Lilly and Company completed its acquisition of Protomer, a pre-clinical stage biotechnology company. Under this acquisition, the company aimed to help Protomer in enhancing its diabetes range with its innovative technology.

Feb-2021: Merck took over VelosBio, a privately held clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to boost its expanding oncology portfolio while also strengthening its long-term growth potential.

Aug-2020: Johnson & Johnson completed its acquisition of Momenta Pharmaceuticals, a biotechnology company. This acquisition aimed to strengthen Janssens position in the autoimmune diseases sector and offer a major catalyst for sustained growth of the company.

Approvals and Trials:

Sep-2020: Baxter International received the US FDA approval for its Clinimix and Clinimix E. The new formulations aimed to complement the offerings of medical formulations with their higher protein content.

Scope of the Study

Market Segments covered in the Report:

By Product

Monoclonal Antibodies

Human Growth Hormone

Fusion Protein

Insulin

Erythropoietin

Interferon

Follicle Stimulating Hormone

By Application

Metabolic Disorders

Immunologic Disorders

Hematological Disorders

Cancer

Hormonal Disorders

Genetic Disorders

Others

By Geography

North America

o US

o Canada

o Mexico

o Rest of North America

Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

Abbott Laboratories

Baxter International, Inc.

Amgen, Inc.

F. Hoffmann-La Roche Ltd.

Eli Lilly And Company

Merck & Co., Inc.

Johnson & Johnson (Janssen Global Services, LLC)

Pfizer, Inc.

Novo Nordisk A/S

Sanofi S.A.

Unique Offerings

Read the original:

The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast...

New York, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Rapid growth of the pharmaceutical realm and higher prices of existing biological drugs are likely to foster attractive growth avenues in the biosimilars market. Biosimilars market is expected to reach US$ 100.5 Bn by the year 2032 as compared to the value of US$ 30.1 Bn at present. The market is slated to witness a CAGR of 14.1% between 2022 and 2032

Biosimilars are known for various economic and clinical benefits, which are poised to take the entire healthcare vertical by storm in the near future. RND Corporation has also certified that increasing frequency of these drugs worldwide is likely of increasing direct spending regarding biologics by close to US$ 54 Bn by the year 2026.

At the same time, easy availability of generic drugs is likely to restrain the biosimilars market in the forecast period.

Request for sample copy of report: https://www.persistencemarketresearch.com/samples/2782

Key Takeaways from Biosimilars Market

Biosimilars cost-effectiveness renders them one of the preferred choices to treat several rare and chronic diseases at the global level. says an analyst belonging to Persistence Market Research

Get customized report as per requirement: https://www.persistencemarketresearch.com/request-customization/2782

Market Competition

Persistence Market Research has mentioned about the key developments in biosimilars market. They include partnerships, agreements, collaborations, and likewise.

Get full access of report: https://www.persistencemarketresearch.com/checkout/2782

What does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the biosimilars market in its latest study, presenting historical demand assessment of 2016 2021 and projections for 2022 2032.

The research study is based on the type of product (recombinant glycosylated proteins and recombinant non-glycosylated proteins), by application (hematology, growth hormone deficiency, oncology, diabetes autoimmune, disease, and likewise), and distribution channel (online pharmacies, hospital pharmacies, and retail pharmacies).

Other Trending Reports:

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies/clients shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Rajendra Singh

Persistence Market Research U.S. Sales Office:305 Broadway, 7th FloorNew York City, NY 10007+1-646-568-7751United StatesUSA - Canada Toll-Free: 800-961-0353Email: sales@persistencemarketresearch.com

Visit Our Website:https://www.persistencemarketresearch.com

Rapid growth of the pharmaceutical realm and higher prices of existing biological drugs are likely to foster attractive growth avenues in the biosimilars market.

See original here:

Biosimilars Market to reach a size of US$ 100.5 Bn by the end of 2032 - GlobeNewswire

New medicines are usually protected by a patent covering the active molecule. These basic or primary patents usually provide robust protection for the relevant product, provided that the compound is genuinely new and inventive. Developers may be able to extend patent protection by patenting other technological advances related to the drug such as new formulations, dosage forms or regimens, and new combinations with other pharmaceuticals. These secondary patents can provide a significantly extended period of patent protection for the drug, provided of course that they are valid.

The same principles apply to the patenting of biological drugs (biologics). Biologics include large peptides and recombinant proteins such as insulin and growth hormone, monoclonal antibodies, recombinant DNA, antibody-drug conjugates, fusion proteins and synthetic vaccines. In contrast, small molecule drugs are usually chemically and thermally stable with low molecular weights.

Given the often significantly greater expense involved in the development of biologics (compared to small molecule drugs), and originator companies need to recoup that cost, it is unsurprising that secondary patents often play a key role in the lifecycles of biologics. As the basic patents on blockbuster biologics expire, there will be increasing interest in testing the strength of secondary patents, particularly from companies that produce biosimilars.

Patents for biologic and small molecule combinations

Secondary patents for drug therapy combinations can cover co-formulations (where the active ingredients are combined in a single product), combination products (such as dual-barrel syringes) and co-administration of different products simultaneously. For the purpose of this article, drug combinations are considered in their broadest sense, that of co-administration.

It is now common medical practice to use biologics in combination therapy, usually with a small molecule drug. But are the secondary patents to this kind of drug combination worthy of patent protection?

One reason why patents for biologic and small molecule combinations may not always be robust is because the co-administration of two or more medicines to treat disease is often a routine medical practice. In some fields, notably HIV medicine and oncology, monotherapy is unusual. This practice has transformed the efficacy of treatment of many diseases. As such, drug combinations which include at least one routinely used drug (often a small-molecule compound) are likely to be considered obvious from a patentability perspective, particularly where that drug is used in other combinations.

The approach of the European Patent Office (EPO)

Inventions are only entitled to patent protection if they are new and not obvious to a skilled person working in the relevant technical field. However, the approach of the EPO to the assessment of whether an invention for a combination of drugs is obvious tends to favour patent applicants. This is because the EPO does not, as a matter of routine, consider evidence on this question from relevant experts (although such evidence may be submitted by third parties opposing the grant of a patent). Rather, the EPOs analysis centres on whether the disclosure of earlier prior art documents would make the invention obvious. If an applicant is able to provide data to the EPO which demonstrates that a combination of drugs is particularly efficacious, a patent is often granted. This can be the case even if one of the drugs is already in routine use for the claimed medical indication. This is because, if one of the claimed drugs is relatively new, there are unlikely to be any prior art publications which disclose that the particular combination works.

Whether a combination is considered obvious may also depend on the medical field in which the compounds are used. In some specialities, routinely-used combinations tend to contain the same backbone drug, with variation only in the remainder of the combination.

As an example, combination therapies for rheumatoid arthritis commonly contain the antifolate drug methotrexate (MTX). Although biologics may only be prescribed when conventional disease-modifying antirheumatic drugs (DMARDs) have not worked, they are often administered in combination with MTX. Some, such as adalimumab and certolizumab pegol, are primarily licensed for combination use and only used alone in cases of intolerance to MTX.

In cancer care, combination chemotherapy is the gold-standard for many malignancies. This includes regimens using biologicals such as obinutuzumab (Gazyvaro) which is only licensed in the UK for combination chemotherapy, although it may be given on its own for subsequent maintenance therapy.

Similarly, pembrolizumab (Keytruda) is licensed for use with a number of longstanding chemotherapy drugs and, for some indications, with newer classes of chemotherapeutic agents such as the multi-receptor tyrosine kinase inhibitors (for example, lenvatinib).

Obvious drug combinations: examples

Some major biologics have had secondary patents to combinations with small molecule drugs revoked in opposition proceedings before the EPO. One example is rituximab, a chimeric mouse/human monoclonal antibody for the CD20 protein found on the surface of B-lymphocytes that is marketed by Roche in Europe as MabThera and by Genentech in the US as Rituxan.

Rituximab was the first therapeutic antibody approved for oncology patients. It was first authorised in the US in November 1997 and in the EU in 1998 for a particular form of non-Hodgkins lymphoma (a type of blood cancer). Further approvals followed for other medical indications unrelated to cancer, as well as different treatment regimens and drug combinations.

Rituximab is now licensed to treat several autoimmune diseases and was approved in Europe in 2008 in combination with MTX to treat rheumatoid arthritis. A European patent granted to Genentech covering this indication was subsequently revoked in opposition proceedings after an appeal to the Technical Board of Appeal (TBA) of the EPO.

The TBA considered that the patent (EP1176981) was obvious because medical practice at the relevant time was to combine virtually all new agents with MTX. It therefore would have been obvious to combine a new biological agent such as rituximab with MTX. There was also an incentive for this to happen, given the urgent need for improved treatments for rheumatoid arthritis. As a result, the patent was not inventive and was revoked.

Another example is the combination of trastuzumab (the originator product Herceptin) and a taxoid to treat malignant HER2-positive breast cancer. Genentechs EP1037926, covering this indication, was revoked during opposition proceedings in the EPO on the basis that the invention was obvious. In those proceedings, the TBA summarised the approach of the EPO in considering obviousness as follows: a course of action can be considered obvious if the skilled person would have carried it out in expectation of some improvement or advantage. Thus, obviousness is not only present when results are clearly predictable but also when there is a reasonable expectation of success In the case of the trastuzumab combination, because monotherapy with the taxoid drug paclitaxel was a well-known treatment for breast cancer and the two drugs are directed at different molecular targets, the TBA considered that it would be obvious to combine them.

The approach of the UK courts

Despite these examples, it is likely that EPO will grant many more combination patents for biologics and small molecules where the patentee is able to provide evidence of an unexpected treatment benefit. The UK courts usually do not take the same approach to obviousness as the EPO, so these patents may be vulnerable to attack. Of particular importance is the role which experts play in invalidity proceedings in the UK, where their opinion can provide valuable context about common clinical practices at the relevant priority date. This is in contrast to the more limited, document-based review performed by the EPO.

It is, of course, possible that in certain medical fields where monotherapy is standard or at least common, drug combinations may be more likely to be considered genuinely inventive. However, combination therapy is, in principle, nothing new in medicine, leaving open the prospect of invalidity challenges to granted patents to many biologic-small molecule combinations.

Originally posted here:

Patents to biological medicines in combination: is two really better than one? - Lexology

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of childbearing age. There are multiple side effects of PCOS. This disorder disturbs the bodys hormonal balance and results in irregular or extended menstrual cycles. PCOS causes follicles with immature eggs to form cysts which begin to grow inside the ovaries and not mature. The inability to develop mature eggs might interfere with ovulation and result in issues such as infertility.

PCOS is closely associated with insulin resistance and higher levels of the hormone testosterone. Numerous factors, including family history, insulin resistance, obesity, sedentary lifestyle, etc., have an impact on PCOS.

PCOS may cause several problems such as fertility issues, infrequent or prolonged periods, weight gain, depression, excess body hair growth and acne, hair loss, hypertension and diabetes. With lifestyle changes and additional stressors due to the Covid-19 pandemic, India has seen a spike in PCOS cases in recent times.

One in every sixth diabetic person over the world is an Indian. India is one of the top 10 countries with the most diabetics, with over 77 million individuals living with the disease. While diabetes is affecting people world over, it is becoming a greater challenge for women suffering from PCOS.

Type 2 diabetes mellitus and PCOS have long been believed to be related. As per a research by All India Institute of Medical Sciences (AIIMS), one in four women suffer from PCOS and over one in 10 women between the age group of 35 to 49 suffer from diabetes.

A woman with PCOS experiences endocrine system disruption and an increase in androgen, often known as male hormone. It is also believed that high quantities insulin are produced by the pancreas as a result of insulin resistance by the insulin receptors, causing PCOS. Thus, women who develop PCOS as young adults are more likely to develop diabetes and, possibly heart problems in later life.

Womens capacity to conceive is negatively impacted by both type 1 and type 2 diabetes, which are both characterized by irregular or non-existent menstruation (oligomenorrhea) and/or secondary amenorrhea. These issues are all closely related to obesity.

Diabetes can also affect fertility in women by delaying the onset of menstruation (or menarche). This can lead to high sugar, causing rapid and early ovarian aging as evidenced by pre-mature menopause. Particularly in women of childbearing age, diabetes is linked to irregular menstrual cycles. Thus, diabetes can impact the biological clock and limit a females reproductive lifespan.

In simple words, Secondary Infertility is the inability to become pregnant for a second time. Secondary infertility is a serious issue that happens more frequently to couples than one may think.

Hormonal imbalances (whether too high or too low) can cause the brain-ovary relationship to be disrupted. The ovary doesnt get the word that its intended to release an egg every month if the brain doesnt provide the right signals. Some of these hormonal abnormalities may manifest themselves later in life. Thyroid, pituitary gland, or a diagnosis of polycystic ovary syndrome are all examples of hormonal imbalances.

Secondary (and main) infertility is frequently brought on by PCOS, which can interfere with ovulation. One should consult their doctor to determine whether they have PCOS when their periods are erratic or non-existent.

To avoid the side effects of PCOS in the long run, women dealing with it should adopt healthy lifestyle habits. Regular exercise would aid in reducing insulin resistance in the body, fight obesity, and burn off extra sugar.

For the body and mind to remain in good shape, a well-balanced nutritional diet rich in proteins, whole grains, and healthy fats, as well as lots of fresh fruits and vegetables, is essential. Getting enough sleep is essential for hormone regulation and stress reduction.

Making such healthy lifestyle changes and choices can play key role in curbing hormonal imbalances in the body and reducing the risk of diabetes and or PCOS. It is also advised to consult your doctor for diagnosis and treatment plan, especially if one is planning to conceive a child.

Go here to see the original:

PCOS awareness: Know how it is linked to diabetes and secondary infertility - Health shots

Touted to be one of the best in the food and skincare world, this oil has numerous health and beauty benefits to offer. Hair fall has become a common problem these days, but no one likes to lose their precious and beautiful tresses. No one wants to wake up and see hair on the pillow - but is there any solution for this? Yes, there is! First things first, it is important to follow a proper hair care routine to prevent hair fall and make your hair stronger. Olive oil for hair works as a boon, as it is laden with ingredients that improve hair texture, prevent split ends, and boost hair growth. There are many benefits of olive oil, and also many ways to use it to stimulate hair growth. From benefits to tips to use it for hair, we have covered it all here. Let us first take a look at the benefits of olive oil.

1. It boosts hair growth

A study conducted on mice showed that oleuropein, a compound in olives stimulates hair growth.

Apart from that, massaging the scalp with olive oil improves blood circulation, which makes hair grow faster.

2. Olive oil helps in reducing DHT production

One of the major factors contributing to hair fall is DHT production.Dihydrotestosterone, commonly known as DHT, is a hormone and a derivative of testosterone. When this hormone is excessively produced by the body, it causes hair fall. It interferes with the cycle of hair growth and makes it easier for hair to fall out in clumps.

Oleic acid present in olive oil inhibits 5-alpha reductase, an enzyme that is responsible for converting testosterone into DHT, which in turn reduces the production of DHT.

So, massage your hair with olive oil to block DHT production and make your hair shinier and stronger.

3. It provides great nourishment to hair

Massaging your scalp with olive oil not only improves blood circulation but also nourishes hair follicles. The nutrients and unsaturated fats present in olive oil prevent dryness by locking moisture in the hair shaft.

4. It prevents hair breakage

Olive oil soothes the scalp and prevents dryness, which in turn reduces hair breakage and makes hair appear voluminous. It is rich in omega-3 fatty acids that condition the hair and make them stronger.

5. Olive oil is great for scalp health

Dandruff is an irritating problem and can annoy anyone. Olive oil helps soothe irritated scalp and prevents problems like dryness, itchiness, dandruff, and so on.

6. It reduces split ends

Olive oil is not suitable to repair split ends, but as it has moisturizing properties, it helps in increasing hair elasticity and preventing split ends. So, if you want to keep your hair soft, healthy and prevent split ends, then use olive oil.

7. It keeps the scalp hydrated and nourished

Olive oil has emollient properties as it contains oleic acid that penetrates deep into the hair shaft to lock moisture and keep the scalp nourished.

These were the top 7 benefits of olive oil for scalp and hair. But, how to use olive oil for hair growth? Below are some DIY hair care tips that you should follow as a part of your regular hair care regimen.

1. Egg and olive oil for hair growth

Ingredients to be used:

Method

Take two eggs and whisk the egg whites along with olive oil in a bowl. Keep whisking till you get a smooth paste, and apply this pack to your hair and scalp. Wear a shower cap to avoid ruining your clothes, and keep the mixture on your scalp and hair for about 15 to 20 minutes. Rinse it off properly with cool water and a gentle shampoo.

You can repeat the process once a week to get soft and shiny hair.

Benefits of egg white and olive oil hair pack

Eggs are a superfood and are loaded with biotin, vitamin A, vitamin E, healthy fats, and folate; all of which replenish moisture and make hair stronger. When combined with olive oil, this pack can do wonders to your hair.

2. Holy basil, neem, and olive oil

Ingredients to be used:

Method

Take a handful of neem leaves and holy basil leaves and grind them properly to turn them into powdered form. Add neem and tulsi powder to olive oil and mix well. Apply this paste to your hair and massage gently using your fingertips for 2 to 3 minutes. Let the neem-tulsi-olive oil pack stay on your hair for 30 minutes, and rinse it off using a mild shampoo.

You can try this recipe once a week for the best results.

Benefits of this hair pack

Neem leaves fight dandruff effectively, Holy basil leaves (Tulsi leaves) make hair roots healthy, and olive oil provides awesome nourishment to hair.

3. Olive oil and coconut oil for hair

Ingredients to be used:

Method

Take three tablespoons of extra virgin coconut oil and heat it slightly in a bowl. Do not overheat. Mix it with olive oil and massage this gently from the root to the tips of your hair. You can keep it overnight and wash your hair the next day in the morning.

You can try this remedy once or twice a week to prevent itchiness, and stimulate hair growth.

Benefits of coconut oil and olive oil hair pack

Coconut oil for hair growth works as a boon as it keeps the scalp moisturized and hydrated. Olive oil prevents dryness and boosts hair growth.

4. Olive oil and banana for hair

Ingredients to be used:

Method

Take a ripe banana, peel it, chop it, and blend it to make a puree. Add a tablespoon of extra virgin olive oil to banana puree and whisk well to form a smooth consistency. If your hair is extremely dry, you can also add 1/2 tablespoon of organic honey to it. Keep this on your hair for 20 minutes and wash it off properly using a mild, sulfate-free shampoo.

Use this hair pack once or twice a week to keep your scalp nourished and moisturized.

Benefits of banana and olive oil hair pack

Bananas have a host of benefits for hair- it adds luster to hair, eliminates dandruff from the scalp, promotes hair elasticity, protects hair against UV damage, and makes hair frizz-free. This hair pack solves various hair problems including dryness, itchiness, dandruff, hair fall, and so on.

5. Olive oil and rosemary oil for hair fall

Ingredients to be used:

Method

This is a simple hair pack to make, all you need to do is just combine the oils and heat the mixture for about 15 to 20 seconds. Massage the olive-rosemary oil blend into your scalp for 10 minutes. Wait for 30 to 40 minutes and let the oil do its magic. Use a gentle shampoo and lukewarm water to wash your hair.

You can follow this DIY recipe for hair two to three times a month.

Benefits of olive oil and rosemary oil for hair

Rosemary oil fights inflammation and improves circulation, thereby preventing various scalp problems. Olive oil and rosemary oil gives shine and strength to tresses.

6. Olive oil, honey, and cinnamon for hair loss

Ingredients to be used:

Method

Take all the ingredients and mix them properly in a bowl to get a smooth mixture. Apply the cinnamon-honey-olive oil mixture onto your hair and leave it on for 20 minutes. Wear a shower cap to avoid a mess. Rinse your hair properly with cool water and a mild shampoo.

Benefits of cinnamon, olive oil, and honey hair mask

Cinnamon stimulates hair growth, prevents hair fall, treats scalp acne, and reduces split ends. Honey keeps the scalp hydrated and makes hair soft and smooth. This hair pack works best for dry hair.

You can try this DIY hair care tip once a week for hair growth.

7. Avocado and olive oil for hair

Ingredients to be used:

Method

Take a ripe avocado and blend it to get its puree. Make sure to blend well so that there are no lumps. Mix it with two to three tablespoons of olive oil and apply this avocado-olive oil hair mask properly. If you want extra hydration, you can also add a tablespoon of honey to it.

Wash your hair thoroughly after half an hour.

Benefits of avocado and olive oil hair mask

Avocados are rich in biotin which helps hair grow faster. Apart from that, it also includes potassium and magnesium that seal cuticle cells and make hair shinier, and also prevent hair breakage.

8. Olive oil and fenugreek for hair

Method

Take a handful of fenugreek seeds and blend them to form a smooth powder. Add two tablespoons of olive oil in it, and massage this mixture onto your scalp and hair. Leave the olive oil-fenugreek pack on your hair for 40 to 45 minutes, and then wash it off using mild shampoo and lukewarm water.

You can repeat this once a week to get gorgeous tresses.

Benefits of olive oil and fenugreek hair pack

Fenugreek seeds are packed with protein and iron, two essential nutrients for hair growth. They also include saponins and flavonoids that prevent fungal problems and induce hair growth. This is a highly effective hair mask for hair growth, dryness problems, and itchiness.

Important things to keep in mind before you try these masks:

Olive oil works for all hair types, but people with fine hair should use only a few drops, and use the mask only once a week. People with thick hair can use more olive oil and consider using the masks two times a week.

Also, it is important to shampoo your hair thoroughly using mild shampoo to get rid of the hair mask.

There are so many brands of olive oil in the market that sometimes it becomes difficult to choose the best olive oil for hair.

You should always choose unrefined, cold-pressed extra-virgin olive oil for your hair. Many people use olive oil used for cooking on their hair, but if you want to reap all the benefits of this hair-friendly oil, then you should opt for oil that is specifically formulated for hair and scalp problems.

Olive oil is a miracle cure for hair loss. Try olive oil for hair growth and make everyday 'happy hair day.'

Also Read:Top 10 benefits of using aloe vera gel for face

Read the rest here:

Top 7 benefits of olive oil for hair growth and ways to use it - PINKVILLA

A new meta-analysis finds that treatment with growth hormone in IVF is associated with improved reproductive outcomes largely mediated by an effect on endometrial function, especially in poor responders.

A multitude of studies have already examined the role of GH in its effect on oocyte quality, and thereby success rates, but without clear conclusions. A Cochrane review from 2021 described the result of adjuvant GH in normal IVF responders as very uncertain, both in terms of LBR and gonadotrophin dose.(2) The effect on LBR was similarly uncertain in poor responders, although the Cochrane reviewers did report a slight increase in the number of oocytes retrieved and in pregnancy rate. The improvement in oocyte yield seen in some of these studies has been one reason for proposing a beneficial effect of GH in IVF.

The more upbeat note in this latest meta-analysis depends less on the effect of GH on oocyte quality (and yield) and more on implantation failure, two-thirds of which, the authors estimate, may be attributed to inadequate uterine function. Indeed, they add, abnormal endometrial function is major challenge to fertility worldwide, with therapies which address endometrial function urgently needed. Thus, many of the trials investigating the effect of GH on IVF outcome have tended to concentrate on poor responder patients and oocyte quality and number, while the effects on the endometrium and in other [patient] populations are largely overlooked. Clinics are thus left in a cloud of uncertainty over GH dose and timing in IVF protocols or even an appropriate patient population who might benefit.

One recent trial in implantation failure patients treated with donor eggs found that those in the GH arm had significantly greater endometrial thickness (and LBR) than those not receiving GH prompting the authors to explain the improvement via beneficial actions on endometrial receptivity.(3) It was studies like this which were the basis of this latest Update analysis, which included a total of 25 trials, the majority in poor responders but all investigating the effect of GH on IVF outcome. The majority of these studies (n = 17) showed that GH administration significantly increased endometrial thickness (mean difference 0.38 mm), which contributed to an improved LBR (OR 1.67). It was further reported from the nine trials examining the effect of GH on endometrial thickness that GH given daily (<5 IU per day) in the follicular phase of the previous cycle or during GnRH agonist long protocols had a greater effect than did the other administration times or ovarian stimulation protocols.

The authors stress as do so many meta-analyses the heterogeneity and moderate quality of their source studies, but seem confident to state that, in poor responders at least, adjuvant GH not only increased the LBR and implantation rate, but also improved endometrial thickness, with the latter, rather than oocyte or embryo quality, explaining the overall benefit. Thus, a patient population of poor responders or with a thin endometrium might benefit from GH administration. However, they add, there was insufficient evidence to draw a conclusion for GH administration in normal responders.

In attempting to explain the biology of their findings, they reaffirm the positive association between endometrial thickness and IVF outcome: the thicker the endometrium on the day of trigger, the higher the pregnancy rate is.(4) And add that GH has been shown to modulate endometrial growth factors leading to modified cell proliferation and tissue vascularisation and thereby to improved endometrial receptivity.

However, while the conclusions of this review seem focused on the endometrial effects of GH, the authors acknowledge that LBR is the ultimate indicator of efficacy, and many questions remain unanswered not least about GH dose, timing and protocols, though suggesting that cotreatment with the GnRH agonist long protocol might provide even more benefits. However, while concluding that women with a thin endometrium might benefit from GH, they propose that GH treatment should be offered according to personal needs and patient conditions. The optimal GH protocols remain open to further study.

1. Shang Y, Wu M, He R, et al. Administration of growth hormone improves endometrial function in women undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2022; doi.org/10.1093/humupd/dmac0282. Sood A, Mohiyiddeen G, Ahmad G, et al. Growth hormone for in vitro fertilisation (IVF). Cochrane Database Syst Rev 2021; 11(11): CD000099. doi.org/10.1002/14651858.CD000099.pub43. Altmae S, Mendoza-Tesarik R, Mendoza C. Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donationprogram: a randomized controlled trial. J Endocr Soc 2018; 2: 96105.doi.org/10.1210/js.2017-003594. Craciunas L, Gallos I, Chu J, et al. Conventional and modern markers of endometrial receptivity: a systematic review and meta-analysis. Hum Reprod Update 2019; 25: 202223.doi.org/10.1093/humupd/dmy044

Link:

Growth hormone in IVF: the endometrial effect - ESHRE

CHICAGO Two-year-old Sam Luce is right on target, which is amazing, considering he was born three months premature.

"Sam was born just under two and a half pounds," says his father, Ben Luce.

"It's hard to describe the size," said his mother, Maureen Luce.

"Day four was the first time we ever got to hold him," Ben added.

Sam was suffering from necrotizing enterocolitis, or NEC. It causes intestinal tissue to die.

"They suddenly develop abdominal distention, feeding intolerance, bloody stool, and they may develop signs of shock," explained Dr. Isabelle De Plaen, a neonatologist and professor of pediatrics at the Lurie Children's Hospital of Chicago.

Doctors are not sure what causes it, but neonatologists at Lurie Children's Hospital found that the decreased development of tiny blood vessels in the intestines could be caused by lower levels of a particular growth hormone. By injecting mice with this growth hormone, they were able to stop the infection.

"We could find and design therapy that could prevent NEC so babies would no longer need to suffer from this disease," De Plaen said.

Just five days after birth, Sam had two inches of his intestine removed. After 151 days in the NICU, he was finally well enough to go home. Now, he keeps his big brother Jack on the run.

"It just blows my mind," Maureen said. "He has met all of his milestones, developmentally. He's super social, a loving, fun, stubborn two-year-old."

Doctors hope these new insights will open the door to developing novel, new treatments that could promote healthy intestine development in premature babies.

Visit link:

Health Beat: NEC in preemies | Health Beat | wfmz.com - 69News WFMZ-TV